PolyPid Ltd. (PYPD) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Polypid Ltd..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.598 Greetings and welcome to Polypeed's fourth quarter and full year 2025 00:00:05.598 -- 00:00:11.646 conference call. At this time, participants are in a listen-only mode. 00:00:11.646 -- 00:00:16.793 As a reminder, this call is recorded. And I would now like to introduce your 00:00:16.793 -- 00:00:22.100 host for today's conference, Yuda Liebler from ARCS Investor Relations. 00:00:22.100 -- 00:00:25.321 Mr Liebler, you may begin. 00:00:27.740 -- 00:00:32.047 Thank you, Operator, and thank you all for joining PolyPID's fourth quarter and full 00:00:32.047 -- 00:00:38.396 year 2025 earnings conference call. Joining me on the call today will be Dikla Chachkes-Akselblad, 00:00:38.396 -- 00:00:43.885 Chief Executive Officer of PolyPID, Jonny Misalawin, PolyPID's Chief Financial Officer, 00:00:43.885 -- 00:00:48.251 and Ori Warschawski, Chief Operating Officer US of PolyPID. 00:00:48.251 -- 00:00:52.317 Earlier today, PolyPID released its financial results for the three and 12 months ending 00:00:52.317 -- 00:00:57.498 December 31st, 2025. A copy of the press release is available in the investor section 00:00:57.498 -- 00:01:01.601 on the company's website at www.polypid.com. 00:01:03.006 -- 00:01:06.852 I'd like to remind you that on this call, management will make forward-looking statements 00:01:06.852 -- 00:01:09.396 within the meaning of the Federal Securities Law. 00:01:09.396 -- 00:01:13.902 For example, management is making forward-looking statements when it discusses the company's 00:01:13.902 -- 00:01:18.048 regulatory strategy and the anticipated timing and structure of the planned new drug 00:01:18.048 -- 00:01:23.152 application or NDA submission for DPLEX 100, including the rolling submission, the 00:01:23.152 -- 00:01:27.91...